In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(821), t(1517), t(1616) and inv(16) is present in a sample obtained from the subject wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML.
